SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of the Bare Temporary Spur ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark ...

Cardiologists across the country are using a new kind of stent to open blocked arteries, one that actually dissolves over time in the body, leaving behind no trace of metal. Dr. David Rizik and ...

Reflow Medical, a cardiovascular disease-focused medical device company, today announced it has received a CE Mark for the Bare Temporary Spur Stent System to treat de novo or restenotic lesions in ...

The Mount Sinai Medical Center is participating in the nationwide ABSORB III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting ...

Among the challenges that BTK lesions pose are severe calcification and elastic recoil, both of which create issues with drug uptake in the arterial wall, noted Michael Lichtenberg, MD (Vascular ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A new crop of experimental heart stents have passed some key safety and effectiveness tests and may one day offer alternatives to the controversial stents currently used to keep unclogged arteries ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its approval from the FDA early last year. The company said the CE mark opens ...